European Journal of Medicinal Chemistry p. 3765 - 3770 (2009)
Update date:2022-08-03
Topics:
Meppen, Malte
Pacini, Barbara
Bazzo, Renzo
Koch, Uwe
Leone, Joseph F.
Koeplinger, Kenneth A.
Rowley, Michael
Altamura, Sergio
Di Marco, Annalise
Fiore, Fabrizio
Giuliano, Claudio
Gonzalez-Paz, Odalys
Laufer, Ralph
Pucci, Vincenzo
Narjes, Frank
Gardelli, Cristina
The currently approved treatment for hepatitis C virus infections is a combination of Ribavirin and pegylated Interferon. It leads to a sustained virologic response in approximately only half of the patients treated. For this reason there is an urgent need of new therapeutic agents. 2′-C-Methylcytidine is the first nucleoside inhibitor of the HCV NS5B polymerase that was efficacious in reducing the viral load in patients infected with HCV. The application of a monophosphate prodrug approach based on unprecedented cyclic phosphoramidates is reported. Our SAR studies led to compounds that are efficiently converted to the active triphosphate in human hepatocytes.
View MoreAnhui Redstar Pharmaceutical Corp., Ltd
Contact:+86-563-5120837
Address:Jingxian Industrial Development Zone, Anhui , China
HANGZHOU TOYOND BIOTECH CO., LTD
Contact:+86-571-86965177
Address:No. 189, Fengqi East Road, Hangzhou, China
HangZhou HuaYe Chemical Technology Co.,Ltd
Contact:+86-13505815007
Address:hangzhou
Beijing Cooperate Pharmaceutical Co.,Ltd
Contact:86-01060279497
Address:No.507,Building 4,Tianhua Street, Biomedicine industrial Base
Zibo Xiaoguang Chemical Material Co., Ltd
Contact:15954099116
Address:Boshan Development Zone
Doi:10.1007/s00706-012-0851-0
(2013)Doi:10.1039/c2cc35309a
(2012)Doi:10.1021/acs.jmedchem.0c00395
(2020)Doi:10.1016/j.tetlet.2016.06.029
(2016)Doi:10.1007/s11426-013-4925-6
(2013)Doi:10.1021/la303061r
(2012)